|
Market Cap | 69.97B | EPS (ttm) | 5.69 |
P/E | 9.80 | EPS this Y | -17.69% |
Forward P/E | 6.94 | EPS next Y | 11.69% |
PEG | 4.75 | EPS past 5Y | - |
P/S | 0.19 | EPS next 5Y | 2.06% |
P/B | 0.94 | EPS Q/Q | -46.91% |
Dividend | 4.51% | Sales Q/Q | 3.60% |
Insider Own | 0.18% | Inst Own | 82.58% |
Insider Trans | -0.85% | Inst Trans | 0.60% |
Short Float | 1.44% | Earnings | May 01/b |
Analyst Recom | 1.97 | Target Price | 70.54 |
Avg Volume | 10.83M | 52W Range | 53.70 - 83.25 |
|
|
May-07-24 | Downgrade |
TD Cowen |
Buy → Hold |
$99 → $59 |
|
|
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Mahoney Michael F | Director | May 02 '24 | Buy | 54.49 | 9,181 | 500,294 | 9,356 | May 02 04:30 PM | LUDWIG EDWARD J | Director | May 02 '24 | Buy | 53.88 | 1,000 | 53,879 | 21,630 | May 02 04:31 PM | Shah Prem S | EVP and Pres-Pharm, Consumer W | Feb 16 '24 | Sale | 76.95 | 29,473 | 2,267,947 | 39,765 | Feb 16 06:46 PM | LUDWIG EDWARD J | Director | Nov 03 '23 | Buy | 70.47 | 2,000 | 140,930 | 20,630 | Nov 06 10:59 AM | Clark James David | SVP, Cont & Chief Acct Officer | Aug 03 '23 | Sale | 74.92 | 25,759 | 1,930,004 | 4,698 | Aug 04 05:41 PM |
|
|
|
|
Market Cap | 1.96B | EPS (ttm) | 0.51 |
P/E | 49.48 | EPS this Y | -1.67% |
Forward P/E | 7.51 | EPS next Y | 9.50% |
PEG | 5.62 | EPS past 5Y | 3.10% |
P/S | 1.28 | EPS next 5Y | 8.80% |
P/B | 1.24 | EPS Q/Q | -114.34% |
Dividend | - | Sales Q/Q | -3.14% |
Insider Own | 15.36% | Inst Own | 85.06% |
Insider Trans | -0.07% | Inst Trans | 1.28% |
Short Float | 3.95% | Earnings | May 06/b |
Analyst Recom | 3.00 | Target Price | 33.80 |
Avg Volume | 899.79K | 52W Range | 22.36 - 51.12 |
|
|
May-07-24 | Downgrade |
Wells Fargo |
Overweight → Equal Weight |
$45 → $25 |
May-07-24 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
May-07-24 11:33AM
|
Integra's (IART) Q1 Earnings Match Estimates, Margins Down
(Zacks) +8.38% |
11:10AM
|
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q1 2024 Earnings Call Transcript
(Insider Monkey) |
08:02AM
|
Truist Cuts Price Target on Integra LifeSciences Holdings to $25 From $37, Keeps Hold Rating
(MT Newswires) |
07:27AM
|
Wells Fargo Downgrades Integra LifeSciences Holdings to Equalweight From Overweight, Cuts Price Target to $25 From $45
(MT Newswires) |
07:19AM
|
Oppenheimer Downgrades Integra LifeSciences Holdings to Perform From Outperform
(MT Newswires) |
03:02AM
|
Integra Lifesciences Holdings Corp (IART) Q1 2024 Earnings Call Transcript Highlights: ...
(GuruFocus.com) |
01:45AM
|
Q1 2024 Integra Lifesciences Holdings Corp Earnings Call
(Thomson Reuters StreetEvents) |
May-06-24 01:23PM
|
Why Is Medical Device Maker Integra LifeSciences Stock Falling On Monday?
(Benzinga) -19.90% |
12:35PM
|
BioCryst Pharmaceuticals, Freshpet rise; Luminar, Integra fall, Tuesday, 5/6/2024
(Associated Press) |
12:35PM
|
BioCryst Pharmaceuticals, Freshpet rise; Luminar, Integra fall, Monday, 5/6/2024
(Associated Press Finance) |
|
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
De Witte Jan | President & CEO | Mar 11 '24 | Option Exercise | 0.00 | 205 | 0 | 18,555 | Mar 13 04:30 PM | Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL | Mar 10 '24 | Option Exercise | 0.00 | 1,179 | 0 | 1,179 | Mar 12 05:10 PM | De Witte Jan | President & CEO | Mar 10 '24 | Option Exercise | 0.00 | 346 | 0 | 18,696 | Mar 12 05:12 PM | DAVIS ROBERT T. JR. | EVP & President, TT | Mar 06 '24 | Option Exercise | 32.59 | 8,736 | 284,663 | 58,241 | Mar 08 04:22 PM | DAVIS ROBERT T. JR. | EVP & President, TT | Mar 06 '24 | Sale | 36.59 | 8,348 | 305,492 | 49,893 | Mar 08 04:22 PM |
|
|
|
|
Market Cap | 25.60M | EPS (ttm) | -1.25 |
P/E | - | EPS this Y | 4.10% |
Forward P/E | - | EPS next Y | 23.31% |
PEG | - | EPS past 5Y | -21.63% |
P/S | 15.24 | EPS next 5Y | -1.60% |
P/B | 0.33 | EPS Q/Q | 20.51% |
Dividend | - | Sales Q/Q | 29.76% |
Insider Own | 23.67% | Inst Own | 59.55% |
Insider Trans | 0.17% | Inst Trans | -0.18% |
Short Float | 0.72% | Earnings | Apr 30/a |
Analyst Recom | 2.83 | Target Price | 3.96 |
Avg Volume | 2.15M | 52W Range | 0.36 - 6.79 |
|
|
May-07-24 | Downgrade |
BofA Securities |
Buy → Underperform |
|
May-07-24 | Downgrade |
Jefferies |
Buy → Hold |
$10 → $0.50 |
May-07-24 | Downgrade |
H.C. Wainwright |
Buy → Neutral |
$12 → $2 |
|
|
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Waksal Harlan | Executive Chair | Nov 10 '23 | Buy | 2.96 | 25,000 | 74,095 | 261,966 | Nov 13 05:29 PM | PERCEPTIVE ADVISORS LLC | Director | May 31 '23 | Buy | 2.49 | 3,610,832 | 8,999,999 | 11,469,117 | Jun 02 04:11 PM | ANDERSON EDWARD T | Director | May 31 '23 | Buy | 2.43 | 1,805,416 | 4,387,161 | 2,521,745 | Jun 02 04:11 PM | NBVM GP, LLC | 10% Owner | May 31 '23 | Buy | 2.43 | 1,805,416 | 4,387,161 | 2,521,745 | Jun 02 04:15 PM |
|
|
| |
|
Market Cap | 3.19B | EPS (ttm) | 0.41 |
P/E | 79.57 | EPS this Y | 5.33% |
Forward P/E | 12.59 | EPS next Y | 19.24% |
PEG | 6.27 | EPS past 5Y | 19.59% |
P/S | 1.75 | EPS next 5Y | 12.70% |
P/B | 23.73 | EPS Q/Q | -48.16% |
Dividend | - | Sales Q/Q | -2.31% |
Insider Own | 1.08% | Inst Own | 90.20% |
Insider Trans | -11.75% | Inst Trans | -4.30% |
Short Float | 3.48% | Earnings | May 06/a |
Analyst Recom | 2.25 | Target Price | 46.36 |
Avg Volume | 1.24M | 52W Range | 35.36 - 57.73 |
|
|
May-07-24 | Downgrade |
BofA Securities |
Neutral → Underperform |
$48 → $39 |
|
May-07-24 01:00PM
|
Evercore ISI Adjusts Price Target on Teradata to $46 From $58, Maintains Outperform Rating
(MT Newswires) -13.80% |
12:45PM
|
Kenvue, Crocs rise; Disney, Teradata fall, Tuesday, 5/7/2024
(Associated Press Finance) |
12:34PM
|
Teradata (TDC) Q1 Earnings Beat Estimates, Revenues Fall Y/Y
(Zacks) |
12:22PM
|
Why Teradata (TDC) Shares Are Plunging Today
(StockStory) |
12:08PM
|
JMP Securities Adjusts Price Target on Teradata to $60 From $72, Maintains Market Outperform Rating
(MT Newswires) |
12:07PM
|
Teradata's Q1 Cloud Miss Implies More Second-Half Loaded Year Than Expected, Morgan Stanley Says
(MT Newswires) |
11:25AM
|
Teradata Corporation (NYSE:TDC) Q1 2024 Earnings Call Transcript
(Insider Monkey) |
11:19AM
|
Update: BofA Securities Downgrades Teradata to Underperform From Neutral on 'Tougher' Near-Term Setup, Cuts Price Target to $39 From $48
(MT Newswires) |
09:52AM
|
BofA Securities Downgrades Teradata to Underperform From Neutral, Adjusts Price Target to $39 From $48
(MT Newswires) |
07:42AM
|
BofA Downgrades Teradata to Underperform
(MT Newswires) |
|
Teradata Corp. is a cloud data analytics company which is built for a multi-cloud reality and solving data challenges at scale. It operates through the following geographical segments: Americas, EMEA, and APJ. The company was founded on July 13, 1979, and is headquartered in San Diego, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Woods Jacqueline D. | Chief Marketing Officer | Mar 07 '24 | Sale | 38.34 | 1,350 | 51,754 | 78,277 | Mar 08 04:33 PM | Woods Jacqueline D. | Chief Marketing Officer | Mar 06 '24 | Sale | 38.65 | 7,270 | 281,007 | 80,951 | Mar 08 04:33 PM | Cullen-Cote Kathleen R | Chief People Officer | Mar 05 '24 | Sale | 37.57 | 26,275 | 987,231 | 127,595 | Mar 05 06:17 PM | Ashton Hillary | Chief Product Officer | Mar 04 '24 | Sale | 38.55 | 4,621 | 178,140 | 142,287 | Mar 05 06:16 PM | Ashton Hillary | Chief Product Officer | Mar 01 '24 | Sale | 37.45 | 9,743 | 364,875 | 156,704 | Mar 05 06:16 PM |
|
|
|
|
Market Cap | 1.34B | EPS (ttm) | - |
P/E | - | EPS this Y | -64.79% |
Forward P/E | 13.40 | EPS next Y | 29.44% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | 12.70% |
P/B | 1.49 | EPS Q/Q | -74.49% |
Dividend | 1.37% | Sales Q/Q | 3.25% |
Insider Own | 0.52% | Inst Own | 99.82% |
Insider Trans | 29.47% | Inst Trans | - |
Short Float | 3.11% | Earnings | May 02/b |
Analyst Recom | 2.62 | Target Price | 12.05 |
Avg Volume | 2.66M | 52W Range | 8.92 - 22.37 |
|
|
May-07-24 | Downgrade |
Redburn Atlantic |
Buy → Neutral |
$13.40 |
|
|
Vestis Corp. engages in the B2B uniform and workplace supplies category. It provides uniform services and workplace supplies to North American customers from Fortune 500 companies to locally owned small businesses across a broad set of end markets. The company comprehensive service offering includes a full-service uniform rental program, cleanroom and other specialty garment processing, floor mats, towels, linens, managed restroom services, and first aid supplies. Vestis is headquartered in Roswell, GA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Pertz Douglas A | Director | May 03 '24 | Buy | 10.02 | 110,000 | 1,102,079 | 141,136 | May 06 04:51 PM | Holloman James Phillip | Director | May 03 '24 | Buy | 9.93 | 20,200 | 200,548 | 44,132 | May 06 04:54 PM | Scott Kim | President and CEO | Feb 09 '24 | Buy | 19.14 | 15,000 | 287,175 | 183,131 | Feb 12 04:24 PM | Pertz Douglas A | Director | Dec 15 '23 | Buy | 19.60 | 5,120 | 100,352 | 23,697 | Dec 18 05:12 PM | Pertz Douglas A | Director | Dec 14 '23 | Buy | 19.10 | 5,250 | 100,275 | 18,577 | Dec 18 05:12 PM |
|
|
|
|